Impact of Maxigesic on Delirium After Minimally Invasive Lung Surgery in Elderly Patients
Key facts
- Who runs it
- Korea University Guro Hospital
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 4
- People taking part
- 25 people enrolled
- Started
- 15 Jun 2023
- Ended
- 23 Jan 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Acetaminophen and Ibuprofen
- Normal saline
- Record updated
- 5 September 2025
- Why it stopped
- The study was terminated early owing to challenges in completing the research registration process.
Who can take part
- Age
- 65 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Patients aged 65 years or older undergoing minimally invasive lung lobectomy or segmentectomy
Who cannot take part
- Anticoagulants or antiplatelet agents are maintained for up to 5 days before surgery
- Hypersensitivity to the main ingredients and additives of Maxigesic
- Hypersensitivity to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)
- Bleeding tendency (e.g., Spontaneous bleeding)
- Uncontrolled hypertension(HTN) (Systolic blood pressure >180 mmHg)
- High-dose methotrexate (MTX) for cancer treatment
- Preoperative cognitive impairment, dementia, or delirium
- Severe hepatic dysfunction (AST, AST ≥2.5 * upper normal limit(UNL) or Total bilirubin ≥3.0 mg/dl)
- Severe renal dysfunction (eGFR <30 ml/min/1.73m2 or Dialysis)
- Severe heart failure (Left ventricle ejection fraction <30%)
- Alcoholism / Alcohol intoxication
- Severe hematological abnormalities
- Symptomatic asthma in need of treatment
- Barbiturates or tricyclic antidepressants (TCAs)
- Inability to understand the research and instructions for this study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary aim of this interventional study is to investigate the impact of perioperative administration of Maxigesic (combination of acetaminophen and ibuprofen) on delirium after minimally invasive lung surgery in elderly patients. The Maxigesic group receives a total of 5 doses of Maxigesic (20mg/kg, maximum dose per serving: 1g) every 6 h from immediately after anesthesia induction. The control group receives the same volume of normal saline. Researchers compare the incidence and severity of postoperative delirium for 5 days after surgery.
The 2 groups in the trial
- Maxigesic groupTreatment being tested
Treatment: Acetaminophen and Ibuprofen
- Control groupPlacebo, for comparison
Treatment: Normal saline
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Impact of Intravenous Administration of Perioperative Acetaminophen and Ibuprofen Combination (Maxigesic®) on Postoperative Delirium in Elderly Patients Undergoing Minimally Invasive Lung Segmentectomy or Lobectomy
- Record updated
- 5 September 2025